why choose us

First received: June 27, 2023

Clinical Trial: Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Mesothelioma

Study Type: INTERVENTIONAL


Official Title: Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma

Brief Summary: Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.Primary Objectives:The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy.Secondary Objective(s):The…

Read more